Quick Answer
LeonaBio, Inc. reported Cash and Equivalents of $69.28 million for fiscal year 2025.
LeonaBio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $69.28M | +43.0% |
| 2024 | $48.44M | -46.5% |
| 2023 | $90.58M | -5.6% |
| 2022 | $95.97M | -13.2% |
| 2021 | $110.54M | +82.3% |
| 2020 | $60.62M | +2848.7% |
| 2019 | $2.06M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.87M | -69.7% | +5.0% |
| June 30, 2025 | $19.89M | -73.1% | -24.7% |
| March 31, 2025 | $26.42M | -66.0% | -45.5% |
| December 31, 2024 | $48.44M | -46.5% | -29.7% |
| September 30, 2024 | $68.86M | -37.6% | -6.7% |
| June 30, 2024 | $73.83M | -35.0% | -5.1% |
| March 31, 2024 | $77.82M | -26.0% | -14.1% |
| December 31, 2023 | $90.58M | -5.6% | -17.9% |
- LeonaBio, Inc. showed an increase of +43.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, LeonaBio, Inc.’s cash and equivalents has grown by 3269.5% (from $2.06 million to $69.28 million).
- The most recent figure is from LeonaBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: